Carolina Vera Ayala

Carolina Vera Ayala

Auto-generated profile, based on publicly available information

Carolina Vera Ayala

Institute of Allergology, Charité - Universitätsmedizin Berlin, corporate member of Freie Universität Berlin and Humboldt-Universität zu Berlin, Berlin, Germany; Fraunhofer Institute for Translational Medicine and Pharmacology ITMP, Immunology and Allergology, Berlin, Germany

Research Focus & Metrics

Academic Career Length

9Years (2018-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
13 November 2024 in American Journal of Clinical Dermatology
Verified
Journal Article
Open access
PDF file
NRNikolai Dario Rothermel
Nikolai Dario Rothermel
CACarolina Vera Ayala
Carolina Vera Ayala
MGMargarida Gonçalo
Margarida Gonçalo
JFJie Shen Fok
Jie Shen Fok
LHLeonie Shirin Herzog
Leonie Shirin Herzog
PKPavel Kolkhir
Pavel Kolkhir
Urticarial vasculitis (UV) is a rare and difficult-to-treat, small-vessel leukocytoclastic vasculitis presenting with recurrent long-lasting wheals. So far, no guidelines and treatment algorithms exist that could help clinicians with the management of UV. In this review, we describe evidence on systemic treatments used for UV and propose a clinical decision-making algorithm for UV management based on the Urticarial Vasculitis Activity Score assessed for 7 days (UVAS7). Patients with occasional UV-like urticarial lesions and patients with UV with skin-limited manifestations and/or mild arthralgia/malaise (total UVAS7 ≤7 of 70) can be initially treated using the step-wise algorithm for chronic urticaria including second-generation H1-antihistamines, omalizumab, and cyclosporine A. Patients with UV with more severe symptoms (UVAS7 >7), especially those with hypocomplementemic UV, may require a multidisciplinary approach, particularly if underlying diseases, for example, systemic lupus erythematosus, cancer, or infection, are present. Immunomodulatory therapy is based on clinical signs and symptoms, and the drug availability and safety profile, and includes systemic corticosteroids, dapsone, hydroxychloroquine, anti-interleukin-1 agents, and other therapies. The level of evidence for all UV treatments is low. Prospective studies with current and novel drugs are needed and could provide further insights into UV pathogenesis and treatment.

1 November 2025 in British Journal of Dermatology
Verified
Journal Article
Open access
HBHanna Bonnekoh
Hanna Bonnekoh
CACarolina Vera Ayala
Carolina Vera Ayala
FAFelix Aulenbacher
Felix Aulenbacher
MKMaria Kinberger
Maria Kinberger
MRMelba Munoz Roldan
Melba Munoz Roldan
TBThomas Buttgereit
Thomas Buttgereit
Patients with acute spontaneous urticaria who did not develop chronic spontaneous urticaria and patients with acute spontaneous urticaria who progressed to having chronic spontaneous urticaria had similar autoantibody profiles and basophil histamine release assay results. Our results suggest that the presence or absence of autoantibodies does not define a patient with chronic spontaneous urticaria.

9 November 2018 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
CVCarolina Vera
Carolina Vera
JVJorge Vera
Jorge Vera
EBElizabeth Ball
Elizabeth Ball
MCMartin K Church
Martin K Church
MMMarcus Maurer
Marcus Maurer

5 May 2026 in Journal of Investigative Dermatology
Verified
Journal Article
Open access
ATAndrea R. Teufelberger
Andrea R. Teufelberger
UCUrban Cerpes
Urban Cerpes
ADAndrada-Renata Dan
Andrada-Renata Dan
DBDanijela Bokanovic
Danijela Bokanovic
RFRegina Fink-Puches
Regina Fink-Puches
PWPeter Wolf
Peter Wolf
Hymenoptera venom immunotherapy (VIT) is usually effective in inducing long-term tolerance to the allergen. In patients with a clonal mast cell disease (CMD) and Hymenoptera venom-induced anaphylaxis (HVA), however, life-long VIT is recommended, as tolerance to the venom is often lost after VIT termination. We compared blood samples from CMD and non-CMD patients with severe HVA before and more than 3 years under VIT to identify differences that might explain the lack of long-term tolerance in CMD patients. Serum tryptase, IgE, IgG4, KIT D816V variation, as well as circulating T and B cell subsets were analyzed. In addition, the cytokine response of wasp venom-stimulated PBMCs was measured. VIT-treated CMD patients had higher numbers of CD8 effector memory T cells (TEM), while VIT-treated non-CMD patients showed higher frequencies of CD8 central memory T cells (TCM) compared to patients prior to VIT. The IL-6 response to wasp venom was lower in CMD patients, regardless of anaphylaxis and therapy status. The generation of CD8 TCMs during VIT may be necessary for long-term tolerance to wasp venom after VIT.

11 January 2026 in Clinical & Experimental Allergy
Verified
Journal Article
Open access
TBThomas Buttgereit
Thomas Buttgereit
CHClaudia Hayford
Claudia Hayford
CACarolina Vera Ayala
Carolina Vera Ayala
SMSherezade Moñino‐Romero
Sherezade Moñino‐Romero
YXYi‐Kui Xiang
Yi‐Kui Xiang
KWKarsten Weller
Karsten Weller
Summary: CSU AE and CSU W+AE patients show similar rates of autoimmune and autoallergic endotypes. The study supports the current CSU definition and recommendations in the global urticaria guideline.

11 December 2018 in JDDG: Journal der Deutschen Dermatologischen Gesellschaft
Verified
Journal Article
Closed access
PDF file
CVCarolina Vera
Carolina Vera
JVJorge Vera
Jorge Vera
EBElizabeth Ball
Elizabeth Ball
MCMartin K Church
Martin K Church
MMMarcus Maurer
Marcus Maurer